H2 Equity Partners (“H2”) is pleased to announce that it has signed a definitive agreement for the sale of its shareholding in Optegra Eye Health Care (“Optegra” or the “Company”) to MidEuropa (“MidEuropa”), a leading private equity firm with a strong track record in building and exiting national and regional leaders in healthcare. The transaction will complete following regulatory clearance. As part of the transaction, H2 will become a minority investor alongside management who will continue to lead the Company.
Optegra offers a wide range of eye care procedures including cataract, AMD, and vision correction for both public and private patients. The company operates 29 highly integrated state-of-the art facilities and performs more than 100k surgical procedures per year with a focus on industry-leading clinical outcomes and outstanding patient experience.
H2 acquired a majority stake in 2021 and has invested significant capital to accelerate its growth. Alongside the Optegra management team, H2 supported substantial growth and development of the business, opening four UK hospitals, acquiring two bolt-on acquisitions and completed an acquisition in a new territory, Slovakia. As a result revenues and profitability experienced strong growth cementing Optegra as one of the leading ophthalmology groups in Europe.
The Company plans to grow into new geographies and deepen its presence in existing markets through greenfield site development and acquisitions, with a focus on maintaining its industry-leading clinical outcomes and outstanding patient experience.
Eversheds Sutherland (Legal), PWC (Financial), Grant Thornton (Tax), Diligize (IT), Mansfield (Commercial) and Lincoln International (Corporate Finance) acted as exclusive advisors to Optegra and its shareholders.
